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Small-molecule drugs were originally discovered using
compound-based drug discovery: opportunistic discovery
of a biologically active compound, often a natural product
(such as penicillin) followed by a search for a disease that
might be treated with the compound. This remains a com-
mon approach to modern drug discovery (for example,
rapamycin and analogs for use as antifungal agents,
immune suppression agents, anti-cancer agents, and possi-
bly others in the future).
The advent of recombinant DNA accelerated a second
approach -target-based drug discovery - where the thera-
peutic target is selected and subjected to methods that
yield candidate drugs (mechanism-based design, structure-
based design, screening). But this approach has its short-
comings - 97% of drug candidates that enter into clinical
investigation eventually fail, many due to unanticipated
toxicity and many others due to a lack of efficacy despite
successful modulation of the target. Selecting therapeutic
targets based on information derived from surrogates of
patients has proved challenging.
Advances in human biology, including human genetics
and physiology, and in small-molecule science, including
chemistry and chemical biology, are now accelerating a
third approach: patient-based drug discovery. I will present
examples that aim to use: 1) information from heritable or
somatic human genetics in human disease, for example, in
Crohn’s disease and cancer, 2) advances in diversity-
oriented synthetic chemistry and chemical biology to
accelerate the discovery of safe and effective small-mole-
cule therapeutics, and 3) an understanding of the relation-
ship of human genetic variation with drug efficacy.
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